Karyopharm Therapeutics Signs Forbearance Agreement, Limited Waiver To Indentures For Additional Time To Advance Its Myelofibrosis Program; Did Not Pay $15.8M Due Under Sept. 10 Credit Agreement

Benzinga Newsdesk www.benzinga.com Neutral 92.2%

Neg 0% Neu 92.2% Pos 0%

https://www.sec.gov/ix?doc=/Archives/edgar/data/1503802/000119312526388621/d94769d8k.htm

Comments

No comments yet. Be the first!